Exhibit 12.1
INTERCEPT PHARMACEUTICALS INC.
STATEMENT OF COMPUTATION OF RATIOS
| Three Months Ended March | Years Ended December 31, | |||||||||||||||||||||||
| 31, 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||
| Earnings: | ||||||||||||||||||||||||
| Net loss | $ | (89,930 | ) | $ | (412,830 | ) | $ | (226,429 | ) | $ | (283,226 | ) | $ | (67,792 | ) | $ | (43,643 | ) | ||||||
| Add: Fixed charges | 8,045 | 16,029 | 1,267 | 567 | 208 | 109 | ||||||||||||||||||
| Earnings, as adjusted | (81,885 | ) | (396,801 | ) | (225,162 | ) | (282,659 | ) | (67,584 | ) | (43,534 | ) | ||||||||||||
| Fixed charges & preferred stock dividends: | ||||||||||||||||||||||||
| Interest expense | 7,206 | 14,196 | - | - | - | 4 | ||||||||||||||||||
| Estimated interest component of rent expense | 839 | 1,833 | 1,267 | 567 | 208 | 105 | ||||||||||||||||||
| Total fixed charges | 8,045 | 16,029 | 1,267 | 567 | 208 | 109 | ||||||||||||||||||
| Preferred stock dividends | - | - | - | - | - | 2,630 | ||||||||||||||||||
| Total fixed charges & preferred stock dividends | 8,045 | 16,029 | 1,267 | 567 | 208 | 2,739 | ||||||||||||||||||
| Ratio of earnings to fixed charges | n/a | n/a | n/a | n/a | n/a | n/a | ||||||||||||||||||
| Ratio of earnings to combined fixed charges & preferred stock dividends | n/a | n/a | n/a | n/a | n/a | n/a | ||||||||||||||||||
